Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC-Reference-Cited by-同舟云学术

Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC

Published:2021-08 Issue:8 Volume:16 Page:1349-1358
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Yeong Joe,Suteja Lisda,Simoni Yannick,Lau Kah Weng,Tan Aaron C.,Li Hui Hua,Lim Sherlly,Loh Jie Hua,Wee Felicia Y.T.,Nerurkar Sanjna Nilesh,Takano Angela,Tan Eng Huat,Lim Tony K.H.,Newell Evan W.,Tan Daniel S.W.

Funder

National Cancer Centre Singapore

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference38 articles.

1. The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer;Sheng;Oncotarget,2017

2. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond;Pai-Scherf;Oncologist,2017

3. PD-L1 expression testing in non-small cell lung cancer;Teixidó;Ther Adv Med Oncol,2018

5. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N Engl J Med,2016

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacodynamics of Sishen decoction in relieving rheumatoid arthritis: Chemical composition, regulatory pathway and online prediction simulation;Heliyon;2024-09

2. Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer;Annals of Surgical Oncology;2024-08-27

3. Human effector CD8+ T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model;eBioMedicine;2024-08

4. Cell Simulation as Cell Segmentation;2024-04-28

5. The proportion of tumour stroma predicts response to treatment of immune checkpoint inhibitor in combination with chemotherapy in patients with stage IIIB−IV non‐small cell lung cancer;Histopathology;2024-04-25